



Ampyra® (dalfampridine) – First-time generic

- On September 11, 2018, Mylan Pharmaceuticals launched an authorized generic version of Acorda Therapeutics' [Ampyra \(dalfampridine\)](#) extended-release tablets.
 - [Accord Healthcare](#), [Alkem Laboratories](#), [Aurobindo Pharma](#), and [Teva](#) have received FDA approval of AB-rated generic versions of Ampyra; however, launch plans for these generics are pending.
- Ampyra is indicated as a treatment to improve walking in adult patients with multiple sclerosis.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.